Accutane Ruling Could Have Ripple Effect Beyond NJ
A New Jersey judge's breakthrough finding that Hoffmann-La Roche Ltd.'s post-2002 label sufficiently warned that its acne drug Accutane was linked to inflammatory bowel disease gives the drugmaker a definitive edge...To view the full article, register now.
Already a subscriber? Click here to view full article